Abstract: ［Abstract］  Objective〖HTSS〗〓To study the clinical efficacy of deep hyperthermia combined with systemic chemotherapy in the treatment of advanced ovarian cancer and the effect on excision repair cross complementing 1(ERCC1), βcatenin and βtubulin Ⅲ expression.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓A total of 80 patients with advanced ovarian cancer treated in our hospital from May 2013 to May 2015 were randomly selected. The control group received paclitaxel combined with cisplatin chemotherapy. The observation group was treated with deep hyperthermia on the basis of the control group. The levels of ERCC1, βcatenin and βtubulin Ⅲ in the two groups were statistically analyzed, and the survival rate and adverse reactions were analyzed.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓The effective rates of tumor remission and ascites control in the observation group were significantly higher than those in the control group. The mRNA and protein levels of ERCC1 and βcatenin in the observation group were significantly lower than those in the control group. The mean survival time of the observation group was significantly longer than that of the control group, and the survival rate of the observation group was significantly higher than that of the control group. The incidence of myelosuppression was significantly lower in the observation group than that in the control group(P＜0.05).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓The use of deep hyperthermia combined with systemic chemotherapy can effectively inhibit the expression of ERCC1 and βcatenin genes, improve the therapeutic effect, reduce the incidence of adverse reactions, effectively prolong the survival of patients and improve the quality of life of patients.

Key words: ovarian neoplasms, hyperthermia, induced, drug therapy